SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
New molecular assay enables rapid antibiotic resistance result to support use of cost effective and convenient oral antibiotic for gonorrhea treatment
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its
® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae, and sequences in the gyrA gene of the bacteria associated with susceptibility to ciprofloxacin (Cipro), a previously used front-line antibiotic treatment. Currently, ceftriaxone ̶ a painful intramuscular injection ̶ combined with azithromycin, is the front-line treatment for gonorrhea in the U.S. However, ceftriaxone represents one of the last remaining antibiotics used for multi-drug-resistant infections and needs to be utilized sparingly so as not to increase resistance to the drug. Already, there are strains of gonorrhea that are resistant to this treatment.
SpeeDx’s new test will allow doctors to confidently and cost-effectively treat up to 70% of gonorrhea infections with a single oral dose of ciprofloxacin because the test establishes disease susceptibility to ciprofloxacin prior to prescribing.
"The ResistancePlus GC test is the first innovation in gonorrhea treatment in decades,” said Dr. Jeffrey Klausner, Professor of Medicine and Public Health at David Geffen School of Medicine and Fielding School of Public Health, University of California, Los Angeles. “With the continued spread of multi-drug gonorrhea, this test can make a real difference.”
Recent surveillance data shows that susceptibility to ciprofloxacin is as high as 70% in some regions and greater than 50% across the majority of countries contributing surveillance data.1-4 In response to the clear utility of ciprofloxacin, the British Association of Sexual Health and HIV (BASHH) have recently drafted new gonorrhea management guidelines that include the preferential use of ciprofloxacin over ceftriaxone if antimicrobial susceptibility testing results are available prior to treatment.5
“We used a similar test at UCLA in Los Angeles and found that doctors liked the test and were much more likely to prescribe a safer and simpler medicine like oral Cipro tablets instead of using injections like Ceftriaxone,” reports Dr. Klausner.
“ResistancePlus GC is an important next step in our ResistancePlus portfolio and is a welcome addition in managing the extensive antibiotic resistance in N. gonorrhoeae infections,” said Colin Denver, CEO for SpeeDx. “We are already seeing high interest in this test with its clear role in maintaining stewardship of the limited antibiotics still available to treat gonorrhea.”
Resistance Plus GC is the first commercially available molecular test* providing ciprofloxacin susceptibility information and is well placed to support current laboratory molecular testing workflows. “If more doctors use the ResistancePlus GC assay, patients will have a better choice when it comes to treatment and we might make a big difference in controlling antibiotic resistant gonorrhea,” adds Dr. Klausner. “Untreatable gonorrhea is a real threat ̶ use of the ResistancePlus GC assay might stop that.''
*available where CE-mark is accepted, not available in the U.S. or A.U.
N. gonorrhoeae is a bacterium causing gonorrhea, a sexually transmitted infection most frequently causing urethritis in men and cervicitis in women. Gonorrhea can result in infertility or ectopic pregnancy and also increases the risk of acquiring other STIs, including HIV. Transmission from infected mothers to newborns during birth can result in gonococcal conjunctivitis, an infection in the eye (ophthalmia neonatorum).
Prevalence and incidence rates of gonorrhea have been increasing around the world, with corresponding increasing rates of resistance to commonly used antibiotics.6 Recent studies suggest N. gonorrhoeae is threatening to become untreatable as resistance continues to develop against all known antibiotic treatments.6 The currently recommended front-line treatment, ceftriaxone, is the last known effective antibiotic, and several extensively drug resistant strains have now been isolated exhibiting resistance to this and many other available treatments.7,8 Global management strategies for antimicrobial resistance highlight gonorrhea as a priority infection to manage, with more effective use of diagnostic tools listed as a key focus for future development.9
Resistance Plus ® kits are multiplex qPCR tests for detection of infectious diseases and antibiotic resistance markers, respectively. Powered by proprietary Plex Zyme ® and Plex Prime ® technologies, the product line offers high multiplexing capability for better, more streamlined infectious disease management. ResistancePlus test offer more than detection, supporting resistance guided therapy by providing actionable information for laboratories and clinicians alike.
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com
1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018.
2. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
3.Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
4. Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19
5. Fifer H. et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae (Draft).
6. Unemo, M. & Jensen, J.S. 2016. Nat. Rev. Urol..268. Published online 10 Jan 2017. doi:10.1038/nrurol
7. PHE Health Protection Report Volume 12, Number 11. 2018
8. AU DoH Media Statement April17th 2018.
9. Rapid Risk Assessment 7 May 2018. Stockholm: ECDC; 2018.
|Asia Pacific and Europe||United States|
|Global Marketing Manager||RCI Healthcare Public Relations|
|Madeline O’Donoghue||Rick Roose|
|+61 2 9209 4170||+1 415 202 4445|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
President and Co-Founder of Soldaze, Inc. Hired to Lead the Branding Division for TransCanna23.5.2019 09:05:00 CEST | Pressemelding
VANCOUVER, British Columbia, May 23, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Transcanna Holdings Inc. (CSE:TCAN: XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce the hiring of Shawn Shevlin (“Shawn”) the president and co-founder SolDaze, Inc., (“SolDaze”) an organic CBD, THC infused mango line of snacks and treats. Shawn will oversee the newly formed branding division for TransCanna at the Modesto facility, which will be responsible for statewide sales. He has over 25 years of experience in branding agricultural related products as well as a background in sales and operations. TransCanna and SolDaze recently executed a non-binding Letter of Intent in which TransCanna will acquire the business and assets of SolDaze. SolDaze has received numerous awards including first place for packaging design and second place for Infused Edibles at the 2018 Emerald Cup. Together, both companies are working toward the closing of the acquisition. “The TransCanna transition team has b
YPO Global Pulse Survey Finds the Customer is Always Right23.5.2019 09:00:00 CEST | Pressemelding
New YPO Global Pulse Survey Finds That Customers Are the Primary Inspiration for Business Innovation Around the World NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- YPO, the premier global leadership organization for more than 27,000 chief executives, conducted a survey of its members in over 130 countries to get their latest thoughts on innovation and its implications for the future of their businesses. YPO’s 2019 Global Pulse Innovation Survey, conducted between 29 April through 6 May 2019 with more than 1,600 chief executive respondents, confirmed that the majority of global business leaders (57 percent) feel an urgent need to innovate now. Where do they look to find inspiration to innovate? Their customers. Nearly half of global business leaders cited customers as their top source of innovation inspiration (48 percent) with employees (36 percent) ranking second. Consultants (10 percent) and think tanks (7 percent) lag far behind in the minds of respondents. The importance of keeping th
Deloitte and Vlocity Sign New Strategic Agreement to Accelerate Digital Transformation for the Enterprise, on Salesforce23.5.2019 09:00:00 CEST | Pressemelding
New Solutions Offered Through Alliance Help Clients Better Serve the Needs of Customers LONDON, May 23, 2019 (GLOBE NEWSWIRE) -- Vlocity, Inc., a leading provider of industry-specific cloud software and Forbes Cloud 100 company, and Deloitte, signed a new strategic agreement to accelerate organizations’ enterprise digital transformation. Announced today at Salesforce World Tour in London, Deloitte and Vlocity plan to jointly coordinate and deliver new solutions built on Salesforce, the world’s #1 CRM. The alliance will help clients deliver enhanced digital experiences across the enterprise, improve workflows and improve productivity. “We have been working with Vlocity for several years and are excited to take our relationship to the next level,” said Nidal Haddad, principal and U.S. ecosystems and alliances leader, Deloitte Consulting LLP. “By formalizing our collaboration with Vlocity, the combined depth of our industry knowledge in cloud apps and cloud deployments will bring powerful
Euro Manganese Provides Operational Update for the Chvaletice Manganese Project22.5.2019 23:08:00 CEST | Pressemelding
VANCOUVER, British Columbia, May 22, 2019 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V/ASX: EMN) (the "Company" or "EMN"), is pleased to provide an operational update on its 100%-owned Chvaletice Manganese Project (the “Project”) in the Czech Republic, including: the signing of a strategic agreement with a consumer of battery raw materials; an update on the feasibility study and a demonstration plant, including the awarding of two key contracts related to initiation of the Project’s feasibility study and its permitting and environmental impact assessment processes; and certain positive developments with the local communities adjacent to the Project. Mr. Marco Romero, President and CEO of EMN, commented: “We are delighted to report on the Company’s first significant collaboration with an important potential customer, on the appointment of two key contractors in connection with our decision to advance the Project to the feasibility study stage, on ongoing progress with the proposed dev
Gainsight Launches Pulse+, The Online Media Platform for Customer Success Professional Development22.5.2019 18:30:00 CEST | Pressemelding
Premium Offering Includes Industry Training and Certifications, Original Video Series, Exclusive Content and More SAN FRANCISCO, May 22, 2019 (GLOBE NEWSWIRE) -- Gainsight®, the customer success company, announced today Pulse +, a digital subscription service for professional development, community, and career fellowship in the customer success industry. The subscription-based online media platform will combine premium eLearning and industry-grade certifications with exclusive content and behind-the-scenes stories of brands and thought leaders who exemplify the true spirit of customer success. Subscribers will have unlimited and exclusive access to a continuously-updated, year-round program of on-demand training, original video series, podcasts, and more. Pulse+ aims to develop and advance the careers of skilled and aspiring customer success professionals around the world. In 2015, Gainsight created Customer Success University to help customer success professionals learn and apply new
Tricentis Disrupts RPA Market with Resilient Model-Based Automation22.5.2019 17:00:00 CEST | Pressemelding
Model-based automation technology trusted by 1600+ enterprise organizations now drives a dedicated Tricentis RPA offering MOUNTAIN VIEW, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Tricentis today announced the availability of Tricentis RPA, which is differentiated by its award-winning model-based automation technology and radically simplified bot pricing model. Tricentis’ model-based automation technology has over 12 years of research and development behind it, and is currently leveraged by 1600+ enterprise organizations. It is best known for delivering highly-resilient end-to-end automation of complex business processes—supporting over 150 enterprise technologies, from legacy applications to the most modern SaaS-based apps. “To satisfy rapidly-changing customer expectations, organizations must be able to change existing processes and applications with both agility and confidence,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “They need to know that the automati